Therapy News and Research

RSS

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.

24 Jun 2013

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Sanofi announced today that the first Phase 3 study results for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus.

24 Jun 2013

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

Elcelyx Therapeutics announced today that clinical study results confirm that the primary site of action of Type 2 diabetes medicine metformin is in the lower bowel rather than in the circulation.

24 Jun 2013

New data suggest PaQ device can reduce known barriers to insulin therapy among people with type 2 diabetes

CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced that comprehensive data from a study of the company's PaQ Insulin Delivery Device will be presented today and tomorrow at the American Diabetes Association 73rd Scientific Sessions in Chicago, IL. The data suggest that PaQ can reduce known barriers to insulin therapy among people with type 2 diabetes, potentially improving their glycemic control.

24 Jun 2013

EHRA White Book reports on current status of arrhythmia treatments in 55 ESC member countries2

The first European data on lead extraction was released today by the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). The information is published in the EHRA White Book 20131, launched at EHRA EUROPACE 2013 in Athens, Greece, during 23-26 June.

24 Jun 2013

Researchers discover reason behind failed anti-cancer therapy

Researchers at the Hebrew University of Jerusalem and in California have achieved a breakthrough in understanding how and why a promising anti-cancer therapy has failed to achieve hoped-for success in killing tumor cells.

24 Jun 2013

Shield Therapeutics recruits patients for ST10 Phase 3 study for treating iron-deficient anaemia

Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of patients into its pivotal Phase 3 programme of ST10 for the treatment of iron-deficient anaemia. ST10 is a novel form of ferric iron taken orally.

24 Jun 2013

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. announced that following the regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use on April 25, 2013, the European Commission (EC) has granted the marketing authorization for XTANDI™ (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

24 Jun 2013

NeuroSigma's Monarch eTNS System to make Canadian debut at 30th International Epilepsy Congress

NeuroSigma, Inc., a Los Angeles based medical device company, today announced that its Monarch eTNS System for the adjunctive treatment of epilepsy and depression will make its Canadian debut at the 30th International Epilepsy Congress, taking place in Montreal, Canada from June 23 to June 27, 2013.

21 Jun 2013

Weill Cornell public health study sheds light on hidden cost of terrorism

The 9/11 attacks on America appear to have caused about one million former smokers across the country to take up the habit again and maintain it, according to a Weill Cornell Medical College public health study.

21 Jun 2013

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-CC5, an RNAi therapeutic targeting complement component C5.

21 Jun 2013

Researchers report therapeutic strategy that appears to destroy drug-resistant melanomas

An advanced tumor is a complex ecosystem. Though derived from a single cell, it evolves as it grows until it contains several subspecies of cells that vary dramatically in their genetic traits and behaviors.

21 Jun 2013

Research findings suggest potent new therapeutic target for certain types of cancer

Scientists have discovered the survival secret to a genetic mutation that stokes leukemia cells, solving an evolutionary riddle and paving the way to a highly targeted therapy for leukemia.

21 Jun 2013

Combination therapy with myxoma virus and rapamycin can kill glioblastoma multiforme

A combination of the myxoma virus and the immune suppressant rapamycin can kill glioblastoma multiforme, the most common and deadliest malignant brain tumor, according to Moffitt Cancer Center research.

21 Jun 2013

Duke Medicine researchers identify molecular target to prevent onset of epilepsy

Duke Medicine researchers have identified a receptor in the nervous system that may be key to preventing epilepsy following a prolonged period of seizures.

21 Jun 2013

Scientists find way to attack dangerous bacteria that cause eye infections

Much as predators attack their prey in the animal world, there are bacteria that consume and kill other bacteria. Scientists are reporting new progress in putting the predator microbes to work - to attack dangerous bacteria that cause eye infections that lead to blindness and have grown resistant to antibiotics.

21 Jun 2013

Researcher receives NINDS grant to develop DTI for pediatric spinal cord injury diagnosis

Most of the 11,000 new cases of spinal cord injury that are diagnosed each year in the United States occur in people under age 30, and often the sufferer is a child. But smaller spinal cords in children and a lack of adequate imaging technology has created major problems in precisely locating the site of injury. New technological developments in imaging could help clinical specialists design more effective treatment and rehabilitation strategies for pediatric patients.

21 Jun 2013

Rigorous interventions result in fewer infections, deaths associated with hospital-onset C. difficile

Rhode Island Hospital has reduced the incidence of hospital-associated Clostridium difficile (C. difficile) infections by 70 percent and reduced annual associated mortality in patients with hospital-associated C. difficile by 64 percent through successive implementation of five rigorous interventions , as reported in the July 2013 issue of The Joint Commission Journal on Quality and Patient Safety.

21 Jun 2013

New model developed to predict atrial fibrillation stroke risk factors

A more accurate and reliable stroke prediction model has been developed to help physicians decide whether to start blood-thinning treatment for patients with atrial fibrillation, as described in the current online issue of the Journal of the American Heart Association.

21 Jun 2013

Targeting particular signaling pathway can help prevent temporal lobe epilepsy, scientists report

Temporal lobe epilepsy, the most common form of epilepsy, is characterized by recurrent seizures throughout life and often behavioral abnormalities, with devastating impacts on patients and their families. Unfortunately, the condition is often not responsive to anticonvulsants. Now scientists report online June 20 in the Cell Press journal Neuron that targeting a particular signaling pathway in mice can prevent the development of temporal lobe epilepsy with just two weeks of treatment, offering hope that researchers will be able to develop effective drugs to mitigate recurrent seizures and the development of epilepsy.

21 Jun 2013

Therapy News and Research

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

New data suggest PaQ device can reduce known barriers to insulin therapy among people with type 2 diabetes

EHRA White Book reports on current status of arrhythmia treatments in 55 ESC member countries2

Researchers discover reason behind failed anti-cancer therapy

Shield Therapeutics recruits patients for ST10 Phase 3 study for treating iron-deficient anaemia

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

NeuroSigma's Monarch eTNS System to make Canadian debut at 30th International Epilepsy Congress

Weill Cornell public health study sheds light on hidden cost of terrorism

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Researchers report therapeutic strategy that appears to destroy drug-resistant melanomas

Research findings suggest potent new therapeutic target for certain types of cancer

Combination therapy with myxoma virus and rapamycin can kill glioblastoma multiforme

Duke Medicine researchers identify molecular target to prevent onset of epilepsy

Scientists find way to attack dangerous bacteria that cause eye infections

Researcher receives NINDS grant to develop DTI for pediatric spinal cord injury diagnosis

Rigorous interventions result in fewer infections, deaths associated with hospital-onset C. difficile

New model developed to predict atrial fibrillation stroke risk factors

Targeting particular signaling pathway can help prevent temporal lobe epilepsy, scientists report

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News